CenExel Clinical Research, Inc., announced the creation of their Centers of Excellence company, which unites clinical research units to design and execute Phase I-IV trials, including Phase I studies in patient populations, to help pharmaceutical companies improve the time and cost of new therapy development for better patient care.
CenExel operates in Utah, California, Georgia and Maryland.
The CenExel Centers of Excellence include JBR Clinical Research, Atlanta Center for Medical Research (ACMR), Anaheim Clinical Trials (ACT), and CBH Health, research facilities in respective fields: post-operative pain, central nervous system (CNS) disorders, chronic disease management, Asian pharmacokinetic bridging studies, psychiatric illnesses, and others.
"CenExel Centers of Excellence offer pharmaceutical companies and clinical research organizations access to some of the finest investigators and facilities in the world for conducting research," said Tom Wardle, CEO. "We are focused on delivering the highest possible quality through our combined expertise, the engagement of our investigators and staff, and most importantly, our results."
Their principal investigators include Todd Bertoch, MD, Robert A. Reisenberg, MD, Peter Winkle, MD, and Robert E. Litman, MD. Dr. Bertoch also chairs the CenExel Scientific Advisory Board with noted analgesia research experts Stephen Cooper, DMD, PhD, and Paul Desjardins, DMD, PhD.
Kevin Quinn, VP of Business Development and Integration, said, "The level of engagement among staff and patients is a key differentiator with our Centers of Excellence. This commitment has enabled our Centers to routinely meet or exceed patient recruitment goals in hundreds of clinical trials, so we are able to complete studies on-time and within budget."
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.